Please try another search term.
This link is provided solely as a service to our website visitors. UCB, Inc. is not responsible for and does not endorse this third-party website.
Before starting treatment with ZILBRYSQ (zilucoplan), you must complete required meningococcal vaccinations.

Learn about another treatment option for adults living with gMG.
Please see Indication and Important Safety Information for RYSTIGGO.
IMPORTANT SAFETY INFORMATION
INCLUDING BOXED WARNING
ZILBRYSQ is a medicine that affects part of your immune system. ZILBRYSQ may lower the ability of your immune system to fight infections. ZILBRYSQ increases your chance of getting serious meningococcal infections. You must complete your meningococcal vaccine(s). Do not use ZILBRYSQ if you have a serious meningococcal infection when you are starting ZILBRYSQ treatment. ZILBRYSQ may also increase the risk of other types of serious infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae. Pancreatitis and pancreatic cysts have happened in people who use ZILBRYSQ. The most common side effects of ZILBRYSQ include injection site reactions, upper respiratory tract infections, and diarrhea.
What is the most important information I should know about ZILBRYSQ?
ZILBRYSQ is a medicine that affects part of your immune system. ZILBRYSQ may lower the ability of your immune system to fight infections.
Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection. Carry it with you at all times during treatment and for 2 months after your last ZILBRYSQ dose. Your risk of meningococcal infection may continue for several weeks after your last dose of ZILBRYSQ. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.
ZILBRYSQ is only available through a program called the ZILBRYSQ Risk Evaluation and Mitigation Strategy (REMS). Before you can receive ZILBRYSQ, your healthcare provider must:
ZILBRYSQ may also increase the risk of other types of serious infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae.
Call your healthcare provider right away if you have new signs or symptoms of infection.
Who should not use ZILBRYSQ?
Before you use ZILBRYSQ, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of ZILBRYSQ?
ZILBRYSQ may cause serious side effects, including:
The most common side effects of ZILBRYSQ include:
Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ZILBRYSQ. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at www.fda.gov/medwatch or 1-800-FDA-10881-800-FDA-1088. You may also report side effects to UCB, Inc. by calling 1-844-599-CARE [2273].
See the detailed Instructions for Use that comes with ZILBRYSQ for information on how to prepare and inject a dose of ZILBRYSQ, and how to properly throw away (dispose of) used ZILBRYSQ prefilled syringes.
INDICATION
What is ZILBRYSQ?
Please see the full Prescribing Information and Medication Guide for ZILBRYSQ, including the Boxed Warning regarding serious meningococcal infections. Please see the Instructions for Use for the ZILBRYSQ Single-Dose Prefilled Syringe. Talk to your healthcare provider about your condition or your treatment. For more information, go to www.ZILBRYSQ.com or call 1-844-599-2273.